

# Gastrointestinal Pathology and Liver Metastasis

# Gastrointestinal Pathology and Liver Metastasis

*Sanjay Kakar, MD*

Professor  
Department of Pathology  
University of California San Francisco School of Medicine  
San Francisco, California

*Ryan M. Gill, MD, PhD*

Professor  
Department of Pathology  
University of California San Francisco School of Medicine  
San Francisco, California

*Amitabh Srivastava, MD*

Member, Memorial Hospital  
Attending Pathologist, Memorial Hospital for Cancer and Allied Diseases  
Department of Pathology  
Memorial Sloan Kettering Cancer Center  
New York, New York

*A volume in the series*

**SURGICAL PATHOLOGY: A CASE-BASED APPROACH TO DIAGNOSIS**

*Series Editors*

**SANJAY KAKAR, MD**

Professor, Department of Pathology  
University of California San Francisco School of Medicine  
San Francisco, California

**RYAN M. GILL, MD, PhD**

Professor, Department of Pathology  
University of California San Francisco School of Medicine  
San Francisco, California



ELSEVIER

Elsevier  
1600 John F. Kennedy Blvd.  
Ste 1800  
Philadelphia, PA 19103-2899

GASTROINTESTINAL PATHOLOGY AND LIVER METASTASIS

ISBN: 978-0-323-82688-4

**Copyright © 2026 by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.**

For accessibility purposes, images in electronic versions of this book are accompanied by alt-text descriptions provided by Elsevier. For more information, see <https://www.elsevier.com/about/accessibility>.

Books and Journals published by Elsevier comply with applicable product safety requirements. For any product safety concerns or queries, please contact our authorised representative, Elsevier B.V., at [productsafety@elsevier.com](mailto:productsafety@elsevier.com).

Publisher's note: Elsevier takes a neutral position with respect to territorial disputes or jurisdictional claims in its published content, including in maps and institutional affiliations.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further information about the Publisher's permissions policies and our arrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: [www.elsevier.com/permissions](http://www.elsevier.com/permissions).

This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein).

#### Notice

Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds or experiments described herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. To the fullest extent of the law, no responsibility is assumed by Elsevier, authors, editors or contributors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein.

*Executive Content Strategist:* Belinda Kuhn  
*Senior Content Development Specialist:* Himanshi Chauhan  
*Publishing Services Manager:* Deepthi Unni  
*Project Manager:* Gayathri S/Beula Christopher  
*Design Direction:* Amy Buxton

Printed in India

Last digit is the print number: 9 8 7 6 5 4 3 2 1



Working together  
to grow libraries in  
developing countries

[www.elsevier.com](http://www.elsevier.com) • [www.bookaid.org](http://www.bookaid.org)

# Contents

**Contributors, vi**

**Preface, x**

## **Part 1: Esophagus, 1**

---

### **Inflammatory Disorders, 2**

- 1.1 Eosinophilic Esophagitis Versus Reflux Esophagitis, 2  
*Azfar Neyaz and Aatur Dilip Singhi*
- 1.2 Lymphocytic Esophagitis Versus *Candida* Esophagitis Versus Lichen Planus Esophagitis, 7  
*Azfar Neyaz and Aatur Dilip Singhi*
- 1.3 *Candida* Esophagitis Versus Other Neutrophil-Predominant Esophagitis, 12  
*Azfar Neyaz and Aatur Dilip Singhi*
- 1.4 Viral Esophagitis Versus Pill and Corrosive Esophagitis, 15  
*Azfar Neyaz and Aatur Dilip Singhi*
- 1.5 Epidermoid Metaplasia Versus Glycogenic Acanthosis, 19  
*Azfar Neyaz and Aatur Dilip Singhi*
- 1.6 Melanosis or Melanocytosis ("Brown" Esophagus) Versus Acute Necrosis ("Black" Esophagus), 22  
*Azfar Neyaz and Aatur Dilip Singhi*

### **Glandular Dysplasia and Carcinoma, 25**

- 1.7 Columnar-Lined Esophagus Versus Barrett's Esophagus, 25  
*Phoenix Bell and Amitabh Srivastava*
- 1.8 Multilayered Epithelium Versus Barrett's Esophagus, 29  
*Phoenix Bell and Amitabh Srivastava*
- 1.9 Ancillary Stains for the Diagnosis of Barrett's Esophagus, 31  
*Phoenix Bell and Amitabh Srivastava*
- 1.10 Barrett's Esophagus Versus Carditis With Intestinal Metaplasia, 33  
*Phoenix Bell and Amitabh Srivastava*
- 1.11 Reactive Changes Versus Dysplasia (Including "Crypt Dysplasia") in Barrett's Esophagus, 36  
*Phoenix Bell and Amitabh Srivastava*
- 1.12 Low-Grade Versus High-Grade Conventional Dysplasia, 39  
*Phoenix Bell and Amitabh Srivastava*
- 1.13 Conventional Versus Foveolar Dysplasia, 41  
*Phoenix Bell and Amitabh Srivastava*

- 1.14 p53 Immunohistochemistry for Diagnosis of Dysplasia in Barrett's Esophagus, 43  
*Phoenix Bell and Amitabh Srivastava*
- 1.15 High-Grade Dysplasia Versus Intramucosal Adenocarcinoma, 46  
*Phoenix Bell and Amitabh Srivastava*
- 1.16 Early Adenocarcinoma Reporting in Endoscopic Mucosal Resection and Endoscopic Submucosal Dissection Specimens, 48  
*Phoenix Bell and Amitabh Srivastava*
- 1.17 Esophageal Adenocarcinoma Variants, 51  
*Phoenix Bell and Amitabh Srivastava*

### **Squamous Dysplasia and Carcinoma, 54**

- 1.18 Grading and Management of Squamous Dysplasia, 54  
*Phoenix Bell and Amitabh Srivastava*
- 1.19 Typical and Variant Squamous Cell Carcinoma, 57  
*Phoenix Bell and Amitabh Srivastava*

### **Uncommon and Rare Esophageal Tumors and Therapy-Related Changes, 60**

- 1.20 Giant Fibrovascular Polyp Versus Atypical Lipomatous Tumor, 60  
*Diana Agostini-Vulaj and Raul S. Gonzalez*
- 1.21 Leiomyoma Versus Granular Cell Tumor, 63  
*Diana Agostini-Vulaj and Raul S. Gonzalez*
- 1.22 Poorly Differentiated and Undifferentiated Esophageal Carcinomas, 66  
*Diana Agostini-Vulaj and Raul S. Gonzalez*
- 1.23 Diagnostic Challenges in Post-neoadjuvant Esophageal Cancer Resection Specimens, 70  
*Diana Agostini-Vulaj and Raul S. Gonzalez*
- 1.24 Esophageal Adenocarcinoma Versus Salivary Gland-Type Tumors, 74  
*Diana Agostini-Vulaj and Raul S. Gonzalez*
- 1.25 Primary Versus Secondary Esophageal Carcinomas, 77  
*Diana Agostini-Vulaj and Raul S. Gonzalez*

## **Part 2: Stomach, 81**

---

### **Benign Conditions, 82**

- 2.1 Normal Stomach Versus Chronic Gastritis, 82  
*Won-Tak Choi and Gregory Y. Lauwers*
- 2.2 Chronic Gastritis Versus Reactive Gastropathy, 86  
*Won-Tak Choi and Gregory Y. Lauwers*

- 2.3 ***Helicobacter Pylori* Gastritis: To Stain or Not to Stain, 89**  
*Won-Tak Choi and Gregory Y. Lauwers*
- 2.4 **Autoimmune Gastritis Versus *Helicobacter* Gastritis, 93**  
*Won-Tak Choi and Gregory Y. Lauwers*
- 2.5 **Iron Pill Gastropathy Versus Other Gastric Siderosis, 98**  
*Won-Tak Choi and Gregory Y. Lauwers*
- 2.6 **Doxycycline Injury Versus Nonspecific Erosion, 100**  
*Won-Tak Choi and Gregory Y. Lauwers*
- 2.7 **Lanthanum Injury Versus Other Histiocytic Infiltration, 102**  
*Won-Tak Choi and Gregory Y. Lauwers*
- 2.8 **Lymphocytic Versus Collagenous Gastritis, 105**  
*Won-Tak Choi and Gregory Y. Lauwers*
- 2.9 **Gastric Biopsy With Increase in Eosinophils, 108**  
*Won-Tak Choi and Gregory Y. Lauwers*
- 2.10 **Acute Gastritis With Ulcer Versus Cytomegalovirus Gastritis, 110**  
*Won-Tak Choi and Gregory Y. Lauwers*
- 2.11 **Acute Gastritis With Ulcer Versus Adenovirus Gastritis, 113**  
*Won-Tak Choi and Gregory Y. Lauwers*
- 2.12 **Phlegmonous Gastritis, 115**  
*Won-Tak Choi and Gregory Y. Lauwers*
- 2.13 **Chronic Gastritis With Intestinal Metaplasia: To Type or Not to Type, 117**  
*Won-Tak Choi and Gregory Y. Lauwers*
- 2.14 **Chronic Gastritis With Reactive Changes Versus Intestinal-Type Dysplasia, 121**  
*Won-Tak Choi and Gregory Y. Lauwers*
- 2.15 **Chronic Gastritis With Reactive Changes Versus Foveolar Dysplasia, 125**  
*Won-Tak Choi and Gregory Y. Lauwers*
- 2.16 **High-Grade Dysplasia Versus Intramucosal Adenocarcinoma, 128**  
*Won-Tak Choi and Gregory Y. Lauwers*

## **Polyps, 130**

- 2.17 **Hyperplastic Polyp Versus Fundic Gland Polyp, 130**  
*Won-Tak Choi and Gregory Y. Lauwers*
- 2.18 **Hyperplastic Polyp With Dysplasia Versus Intestinal-Type Adenoma, 133**  
*Won-Tak Choi and Gregory Y. Lauwers*
- 2.19 **Pyloric Gland Adenoma Versus Foveolar-Type Adenoma, 135**  
*Won-Tak Choi and Gregory Y. Lauwers*
- 2.20 **Oxyntic Gland Adenoma Versus Other Adenomas, 139**  
*Won-Tak Choi and Gregory Y. Lauwers*
- 2.21 **Hyperplastic Polyp Versus Peutz-Jeghers Polyp, 142**  
*Won-Tak Choi and Gregory Y. Lauwers*
- 2.22 **Multiple Fundic Polyps Versus Gastric Adenocarcinoma and Proximal Polyposis of the Stomach, 144**  
*Won-Tak Choi and Gregory Y. Lauwers*

## **Malignant Epithelial Tumors, 147**

- 2.23 **Gastric Adenocarcinoma: Intestinal Versus Diffuse Type, 147**  
*Won-Tak Choi and Gregory Y. Lauwers*
- 2.24 **Lymphocyte-Rich/Epstein-Barr Virus-Positive Versus Mismatch Repair Deficient Adenocarcinoma, 151**  
*Won-Tak Choi and Gregory Y. Lauwers*
- 2.25 **Hepatoid Carcinoma Versus Poorly-Differentiated Adenocarcinoma, 155**  
*Won-Tak Choi and Gregory Y. Lauwers*
- 2.26 **Enteroblastic Adenocarcinoma Versus Conventional Adenocarcinoma, 158**  
*Won-Tak Choi and Gregory Y. Lauwers*
- 2.27 **Signet Ring Cell Carcinoma Versus Pseudo Signet Ring Cells, 161**  
*Won-Tak Choi and Gregory Y. Lauwers*
- 2.28 **Signet Ring Cell Carcinoma: Sporadic Versus Familial, 164**  
*Won-Tak Choi and Gregory Y. Lauwers*
- 2.29 **Signet Ring Cell Carcinoma: Primary Versus Metastatic, 168**  
*Won-Tak Choi and Gregory Y. Lauwers*
- 2.30 **Sarcomatoid Carcinoma Versus Sarcoma, 171**  
*Won-Tak Choi and Gregory Y. Lauwers*
- 2.31 **Gastroblastoma Versus Adenocarcinoma, 173**  
*Won-Tak Choi and Gregory Y. Lauwers*
- 2.32 **Gastric Adenocarcinoma With HER2 Staining, 175**  
*Won-Tak Choi and Gregory Y. Lauwers*
- 2.33 **Gastric Adenocarcinoma With Programmed Cell Death Ligand 1 Staining, 178**  
*Won-Tak Choi and Gregory Y. Lauwers*
- 2.34 **Well-Differentiated Neuroendocrine Tumor in Autoimmune Gastritis (Type 1) Versus Neuroendocrine Hyperplasia, 181**  
*Won-Tak Choi and Gregory Y. Lauwers*
- 2.35 **Well-Differentiated Neuroendocrine Tumor: Sporadic (Type 3) Versus Other Types (Types 1 and 2) and Neuroendocrine Carcinoma, 184**  
*Won-Tak Choi and Gregory Y. Lauwers*

## **Part 3: Small Intestine, 189**

### **Benign Conditions, 190**

- 3.1 **Gastric Heterotopia Versus Neoplasm, 190**  
*Dorukhan Bahceci and Grace E. Kim*
- 3.2 **Pediatric Small Intestinal Biopsies in Intractable Diarrhea, 193**  
*Soo-Jin Cho*
- 3.3 **Small Bowel Disorders: Celiac Disease and Mimics, 197**  
*Ilke Nalbantoglu and Dhanpat Jain*
- 3.4 **Small Bowel Infection: Protozoal, Microsporidial, Viral, 208**  
*Gillian Leigh Hale*

- 3.5 **Macrophage Infiltrates: Infectious Versus Non-Infectious Etiologies, 214**  
*Gillian Leigh Hale*
- 3.6 **Heterotopic Pancreas Versus Neoplasm, 220**  
*Dorukhan Bahceci and Grace E. Kim*
- 3.7 **Active Ileitis With Crystals Versus Crohn's Disease, 223**  
*Mojgan Hosseini*

## **Polyps, 226**

- 3.8 **Adenoma With High-Grade Dysplasia Versus Invasive Adenocarcinoma, 226**  
*Changqing Ma and Reetesh K. Pai*
- 3.9 **Pyloric Gland Adenoma Versus Brunner Gland Hamartoma, 229**  
*Won-Tak Choi, Gregory Y. Lauwers, and Ryan M. Gill*

## **Tumors, 233**

- 3.10 **Dystrophic Fat Versus Adenocarcinoma, 233**  
*Stephen M. Lagana and Ryan M. Gill*
- 3.11 **Well-Differentiated Neuroendocrine Tumor Versus Neuroendocrine Carcinoma, 237**  
*Nancy M. Joseph and Ryan M. Gill*
- 3.12 **Multilocular Peritoneal Inclusion Cyst Versus Malignant Mesothelioma, 243**  
*Changqing Ma and Reetesh K. Pai*
- 3.13 **Gangliocytic Paraganglioma Versus Well-Differentiated Neuroendocrine Tumor of the Small Intestine, 247**  
*Changqing Ma and Reetesh K. Pai*
- 3.14 **Ampullary Adenocarcinoma (pT2 Vs pT3), 252**  
*Dorukhan Bahceci and Grace E. Kim*
- 3.15 **Small Intestinal Adenocarcinoma Versus Metastatic Adenocarcinoma, 257**  
*Changqing Ma and Reetesh K. Pai*

## **Part 4: Appendix, 263**

### **Benign Conditions, 264**

- 4.1 **Acute Appendicitis With Diverticulitis Versus Low-Grade Appendiceal Mucinous Neoplasm, 264**  
*Dana Balitzer and Sanjay Kakar*
- 4.2 **Sessile Serrated Adenoma Versus Mucosal Hyperplasia, 266**  
*Dana Balitzer and Sanjay Kakar*
- 4.3 **Benign Subserosal Glands (Endosalpingiosis) Versus Adenocarcinoma, 269**  
*Dana Balitzer and Sanjay Kakar*

### **Malignant Tumors, 272**

- 4.4 **Low-Grade Appendiceal Mucinous Neoplasm Versus Appendiceal Adenoma, 272**  
*Dana Balitzer and Sanjay Kakar*
- 4.5 **Low-Grade Appendiceal Mucinous Neoplasm Versus Distended Appendix With Mucin, 274**  
*Dana Balitzer and Sanjay Kakar*

- 4.6 **Low-Grade Appendiceal Mucinous Neoplasm With Serosal Acellular Mucin and Other Risk Factors in Low-Grade Appendiceal Mucinous Neoplasm, 278**  
*Dana Balitzer and Sanjay Kakar*
- 4.7 **Low-Grade Appendiceal Mucinous Neoplasm Versus High-Grade Appendiceal Mucinous Neoplasm, 282**  
*Changqing Ma and Reetesh K. Pai*
- 4.8 **Mucinous Carcinoma Peritonei (Pseudomyxoma Peritonei), Low Grade (Grade 1) Versus High Grade (Grade 2), 286**  
*Changqing Ma and Reetesh K. Pai*
- 4.9 **Mucinous Carcinoma Peritonei (Pseudomyxoma Peritonei), Grade 2 Versus Grade 3, 292**  
*Changqing Ma and Reetesh K. Pai*
- 4.10 **Goblet Cell Adenocarcinoma Versus Neuroendocrine Neoplasms and Conventional Adenocarcinoma, 295**  
*Dana Balitzer and Sanjay Kakar*
- 4.11 **Appendiceal Neuroendocrine Tumor: Low- Versus High-Risk Features, 300**  
*Dana Balitzer and Sanjay Kakar*
- 4.12 **Tubular Neuroendocrine Tumor Versus Adenocarcinoma, 304**  
*Dana Balitzer and Sanjay Kakar*

## **Part 5: Colon, 307**

### **Inflammatory Disorders, 308**

- 5.1 **Infectious Colitis Versus Inflammatory Bowel Disease, 308**  
*Patrick Henn and Lindsey Westbrook*
- 5.2 **Ischemic Versus Pseudomembranous Colitis, 312**  
*Patrick Henn and Lindsey Westbrook*
- 5.3 **Graft-Versus-Host Disease Versus Bowel Prep Effect, 316**  
*Patrick Henn and Lindsey Westbrook*
- 5.4 **Eosinophilic Colitis Versus Infiltrative Disorders With Prominent Eosinophils, 318**  
*Patrick Henn and Lindsey Westbrook*
- 5.5 **Enterocolic Lymphocytic Phlebitis Versus Inflammatory Bowel Disease, 322**  
*Cameron Beech and Dhanpat Jain*
- 5.6 **Lymphocytic Versus Collagenous Colitis, 326**  
*Patrick Henn and Lindsey Westbrook*
- 5.7 **Diverticular Disease—Associated Colitis Versus Inflammatory Bowel Disease, 330**  
*Patrick Henn and Lindsey Westbrook*
- 5.8 **Diversion Colitis Versus Inflammatory Bowel Disease, 333**  
*Patrick Henn and Lindsey Westbrook*
- 5.9 **Isolated Asymptomatic Chronic Colitis and Ileitis Versus Inflammatory Bowel Disease, 336**  
*Patrick Henn and Lindsey Westbrook*
- 5.10 **Drug-Induced Colitis Versus Inflammatory Bowel Disease, 339**  
*Patrick Henn and Lindsey Westbrook*

- 6.3 **Low-Grade Versus High-Grade Squamous Intraepithelial Lesion, 467**  
*Sarah E. Umetsu*
- 6.4 **High-Grade Squamous Intraepithelial Lesion Versus Superficially Invasive Squamous Cell Carcinoma, 471**  
*Sarah E. Umetsu*
- 6.5 **Squamous Cell Carcinoma Versus Basal Cell Carcinoma, 473**  
*Sarah E. Umetsu*
- 6.6 **Squamous Cell Carcinoma Versus Neuroendocrine Carcinoma, 477**  
*Sarah E. Umetsu*
- 6.7 **Anal Gland Adenocarcinoma Versus Rectal Adenocarcinoma, 479**  
*Sarah E. Umetsu*
- 6.8 **Paget Disease Versus High-Grade Squamous Intraepithelial Lesion, 482**  
*Sarah E. Umetsu*
- 6.9 **Anal Melanoma, 485**  
*Sarah E. Umetsu*

## Part 7: Hematopoietic Neoplasms and Mimics, 489

---

- 7.1 **Gastric Extranodal Marginal Zone Lymphoma Versus *Helicobacter pylori* Gastritis With Lymphoid Hyperplasia, 490**  
*Alexander Thomas Kikuchi and Ryan M. Gill*
- 7.2 **Colonic Polypoid Extranodal Marginal Zone Lymphoma Versus Reactive Lymphoid Hyperplasia, 495**  
*Alexander Thomas Kikuchi and Ryan M. Gill*
- 7.3 **Mantle Cell Lymphoma, 499**  
*Kwun Wah Wen and Robert Shigeo Ohgami*
- 7.4 **Duodenal Follicular Lymphoma Versus Reactive Follicles, 502**  
*Alexander Thomas Kikuchi and Ryan M. Gill*
- 7.5 **Colonic Polypoid Follicular Lymphoma Versus Reactive Lymphoid Infiltrates, 505**  
*Alexander Thomas Kikuchi and Ryan M. Gill*
- 7.6 **Diffuse Large B-Cell Lymphoma Versus Other Large B-Cell Lymphomas, 508**  
*Rifat Mannan, Kwun Wah Wen, and Robert Shigeo Ohgami*
- 7.7 **High-Grade B-Cell Lymphoma Versus Other High-Grade Neoplasms, 511**  
*Kunwar Singh, Kwun Wah Wen, and Robert Shigeo Ohgami*
- 7.8 **Enteropathy-Associated T-Cell Lymphoma Versus Other Lymphoma, 514**  
*Kwun Wah Wen, Joshua Robert Menke, and Robert Shigeo Ohgami*
- 7.9 **Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma Versus Other Lymphoma, 517**  
*Naoki Akanuma and Ryan M. Gill*
- 7.10 **Indolent Clonal T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract Versus Lymphoma, 522**  
*Kwun Wah Wen, Robert Shigeo Ohgami, and Joshua Robert Menke*
- 7.11 **Systemic T-Cell Lymphoma Involvement of the Gastrointestinal Tract Versus Primary Gastrointestinal Lymphoma, 525**  
*Kwun Wah Wen, Arzu Sağlam Ayhan, and Robert Shigeo Ohgami*
- 7.12 **Reactive Marginal Zone Hyperplasia Versus Extranodal Marginal Zone Lymphoma, 529**  
*Kwun Wah Wen and Robert Shigeo Ohgami*
- 7.13 **Natural Killer Cell Enteropathy Versus Extranodal Natural Killer/T-Cell Lymphoma, 532**  
*Alexander Thomas Kikuchi and Ryan M. Gill*
- 7.14 **Myeloid Sarcoma Versus Other Hematopoietic or Small Round Blue Cell Tumors, 536**  
*Naoki Akanuma and Ryan M. Gill*
- 7.15 **Systemic Mastocytosis Versus Benign Mast Cells, 541**  
*Kwun Wah Wen and Robert Shigeo Ohgami*
- 7.16 **Classic Hodgkin Lymphoma Versus Mimics, 544**  
*Kwun Wah Wen and Robert Shigeo Ohgami*
- 7.17 **Langerhans Cell Histiocytosis Versus Langerhans Cell Sarcoma, 547**  
*Kwun Wah Wen and Robert Shigeo Ohgami*
- 7.18 **Burkitt Lymphoma Versus Other Lymphoma, 550**  
*Kwun Wah Wen and Robert Shigeo Ohgami*
- 7.19 **Plasmablastic Lymphoma Versus Other Lymphoma, 553**  
*Kwun Wah Wen and Robert Shigeo Ohgami*
- 7.20 **Posttransplant Lymphoproliferative Disorder Versus Reactive Lymphoid Lesions, 555**  
*Kwun Wah Wen and Robert Shigeo Ohgami*
- 7.21 **Rectal Tonsil or Reactive Lymphoid Aggregate Versus Rectal Lymphoma, 559**  
*Kwun Wah Wen and Robert Shigeo Ohgami*

## Part 8: Mesenchymal Tumors, 561

---

- 8.1 **Gastrointestinal Stromal Tumor Versus Smooth Muscle or Neurogenic Tumor, 562**  
*Leona A. Doyle and Kieran Sheahan*
- 8.2 **Inflammatory Myofibroblastic Tumor Versus Other Spindle Cell Neoplasms, 568**  
*Leona A. Doyle and Kieran Sheahan*
- 8.3 **Intraabdominal Desmoid (Mesenteric Fibromatosis) Versus Gastrointestinal Stromal Tumor, 571**  
*Andrew E. Horvai*
- 8.4 **Solitary Fibrous Tumor Versus Other Spindle Cell Neoplasms, 575**  
*Leona A. Doyle and Kieran Sheahan*
- 8.5 **Lipoma Versus Liposarcoma, 579**  
*Andrew E. Horvai*



- 8.6 Inflammatory Fibroid Polyp (Gastric or Small Intestine) Versus Other Spindle Cell Polyps, 584**  
*Ryan M. Gill*
- 8.7 Plexiform Fibromyxoma (Gastric or Duodenum) Versus Other Spindle Cell Lesions, 589**  
*Andrew E. Horvai*
- 8.8 Leiomyoma and Atypical Smooth Muscle Tumor, 593**  
*Andrew E. Horvai*
- 8.9 Leiomyosarcoma Versus Other Spindle Cell Neoplasms, 597**  
*Leona A. Doyle and Kieran Sheahan*
- 8.10 Hemangioma or Arteriovenous Malformation Versus Other Vascular Lesions, 600**  
*Andrew E. Horvai*
- 8.11 Kaposi Sarcoma (Any Gastrointestinal Site) Versus Other Spindle Cell Lesions, 604**  
*Andrew E. Horvai*
- 8.12 Angiosarcoma (Any Gastrointestinal Site) Versus Other Sarcomas, 607**  
*Leona A. Doyle and Kieran Sheahan*
- 8.13 Glomus Tumor (Stomach) Versus Other Neoplasms, 611**  
*Leona A. Doyle and Kieran Sheahan*
- 8.14 Vascular Malformations (Lymphatic, Venous, Arteriovenous) Versus Hemangioma, 614**  
*Andrew E. Horvai*
- 8.15 Schwannoma (Stomach) Versus Other Spindle Cell Lesions, 619**  
*Andrew E. Horvai*
- 8.16 Granular Cell Tumor Versus Atypical Granular Cell Tumor (Esophagus or Large Bowel), 623**  
*Andrew E. Horvai*
- 8.17 Perineurioma or Benign Fibroblastic Polyp (Large Bowel), 627**  
*Soo-Jin Cho*
- 8.18 Ganglioneuroma and Ganglioneuromatosis (Large Bowel), 631**  
*Soo-Jin Cho*
- 8.19 Perivascular Epithelioid Cell Tumor or Angiomyolipoma Versus Other Neoplasms, 634**  
*Leona A. Doyle and Kieran Sheahan*
- 8.20 Synovial Sarcoma (Stomach) Versus Other Sarcomas, 638**  
*Leona A. Doyle and Kieran Sheahan*
- 8.21 Malignant Gastrointestinal Neuroectodermal Tumor and Gastrointestinal Clear Cell Sarcoma (Small Intestine, Stomach, Large Intestine) Versus Melanoma, 642**  
*Nicole Panarelli*

- 8.22 Colonic Ulceration With Pseudomalignant Change, 648**  
*Soo-Jin Cho*
- 8.23 Endometrial Lesions and Their Mimics in the Gastrointestinal Tract, 651**  
*Nicholas Ladwig and Ryan M. Gill*

## Part 9: Systemic Disorders Involving the Gastrointestinal Tract, 659

---

- 9.1 Amyloidosis Versus Normal Biopsy, 660**  
*Catherine E. Hagen and Benjamin J. Van Treeck*
- 9.2 Graft-Versus-Host Disease Versus Mycophenolate Injury, 665**  
*Catherine E. Hagen and Benjamin J. Van Treeck*
- 9.3 Scleroderma Versus Other Autoimmune Disorders, 669**  
*Catherine E. Hagen and Benjamin J. Van Treeck*
- 9.4 Human Immunodeficiency Virus Enteritis Versus Other Immune Deficiency Disorders, 672**  
*Catherine E. Hagen and Benjamin J. Van Treeck*
- 9.5 Esophageal Stricture Versus Immunoglobulin G4 Disease, 675**  
*Benjamin J. Van Treeck and Catherine E. Hagen*

## Part 10: Liver Metastasis, 677

---

- 10.1 Metastatic Adenocarcinoma Versus Intrahepatic Cholangiocarcinoma, 678**  
*Dana Balitzer and Ryan M. Gill*
- 10.2 Resection of Colorectal Cancer Metastasis, 684**  
*Deyali Chatterjee, Eizaburo Sasatomi, and Heather L. Stevenson-Lerner*
- 10.3 Metastatic Small Intestinal Well-Differentiated NET Versus HCC Versus Other Neoplasms, 691**  
*Fahire Goknur Akarca and Sanjay Kakar*
- 10.4 Metastatic Neuroendocrine Carcinoma Versus Adenocarcinoma With Neuroendocrine Features, 699**  
*Dorukhan Bahceci and Sanjay Kakar*
- 10.5 Metastatic Hepatoid Carcinoma Versus Yolk Sac Tumor Versus HCC, 705**  
*Dana Balitzer and Ryan M. Gill*
- 10.6 Metastatic Epithelioid GIST Versus Primary/Metastatic Carcinoma, 710**  
*Raymond H. L. Yip and Sanjay Kakar*
- 10.7 Metastatic Anorectal Melanoma Versus Primary/Metastatic Tumors, 716**  
*Fahire Goknur Akarca and Sanjay Kakar*

## Index, 720



## 1.1

# Eosinophilic Esophagitis Versus Reflux Esophagitis

AZFAR NEYAZ AND AATUR DILIP SINGHI

## Case History With Endoscopic Findings

A 45-year-old male presented with dysphagia and odynophagia for the past 6 months. Upper endoscopy showed linear furrows and rings in the middle third of the esophagus (Fig. 1.1.1).

## Microscopic Findings

The biopsy showed squamous mucosa with  $\geq 15$  eosinophils per high-power field that were concentrated toward the mucosal surface, as well as marked spongiosis and basal cell hyperplasia. A diagnosis of active esophagitis with features consistent with eosinophilic esophagitis (EoE) in the appropriate clinical setting was rendered (Fig. 1.1.2).


## Differential Diagnosis

EoE and reflux esophagitis are the two most common causes of an eosinophil-rich inflammatory cell infiltrate in esophageal biopsies. The distinction between these two diagnostic entities is difficult by histology alone because of a marked overlap in morphologic features. Clinical and endoscopic


correlation is necessary for an accurate diagnosis.<sup>1,2</sup> It is also important to remember that other causes may give rise to intraepithelial esophageal eosinophilia and include infections (e.g., fungal, viral, and parasitic organisms), eosinophilic gastroenteritis, pill esophagitis, graft-versus-host disease (GVHD), vasculitis, drug hypersensitivity, hypereosinophilic syndrome, celiac disease, Crohn's disease, connective tissue disease, and vesiculobullous disorders.<sup>3,4</sup>

## Eosinophilic Esophagitis

The key pathologic features of EoE are an eosinophil-predominant intraepithelial infiltrate with a peak count of  $\geq 15$  eosinophils per high-power field (or  $\sim 60$  per  $\text{mm}^2$ ). The infiltrate can be patchy, and the peak count reflects infiltration in the highest-density area anywhere in the biopsy. Additional findings that are often present and related to the density of the infiltrate include luminal eosinophilic microabscesses, degranulated eosinophils, surface desquamation, basal cell hyperplasia, marked intracellular edema (spongiosis), and lamina propria fibrosis<sup>2,5,6</sup> (Fig. 1.1.3). In general, intraepithelial eosinophilia is more pronounced in EoE than in reflux esophagitis; however, in severe reflux esophagitis,



• **Fig. 1.1.1** The typical endoscopic appearance of eosinophilic esophagitis, which consists of circumferential rings and linear furrows diffusely involving the esophagus.



• **Fig. 1.1.2** Histologic features of eosinophilic esophagitis, which include prominent basal cell hyperplasia, markedly increased intraepithelial eosinophilic infiltrate (typically  $>15$ /high-power field), and subepithelial fibrosis that results in dysphagia.